Travere therapeutics announces interim analysis from the phase 3 protect study of filspari™ (sparsentan) in iga nephropathy published in the lancet and presented at world congress of nephrology 2023

Filspari demonstrated a statistically significant, rapid, and sustained decline of proteinuria compared to the active control filspari demonstrated a statistically significant, rapid, and sustained decline of proteinuria compared to the active control
TVTX Ratings Summary
TVTX Quant Ranking